Fat-binding polymers

1 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a polymer with one or more side chains comprising an aminoalkylpolyol, an ammoniumalkylpolyol, a dialkanolamine, a dialkanolammonium, or a pharmaceutically acceptable salt thereof, provided that the polymer is not:

a poly(N,N-diallyl-N,N-di(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof;

a poly(N,N-diallyl-N-alkyl-N-(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof; or

a poly(N,N-di(2,3-dihydroxypropyl)allylamine) or a pharmaceutically acceptable salt thereof.

2 . The pharmaceutical composition of claim 1 , wherein the polymer is a polymer with monomer units represented by Structural Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

M is a covalent bond, —(CH 2 ) n —, 1,3-phenylene, 1,4-phenylene, —C(O)O—, —C(O)NR 1 , —C(O)—, —O—, —NR 1 —, —N + (R 1 )(R 3 )—, —CH 2 NR 1 —, —CH 2 N + (R 1 )(R 3 ), or —CH 2 O—;

n is an integer greater than 1;

Q is a covalent bond or an inert linking group;

R 1 is —H, an aliphatic group or a substituted aliphatic group;

R 2 is —H or a C1-C6 alkyl group;

R 3 is —H, a C1-C6 alkyl group, or a benzyl group;

W is —NR 4 R 5 , —N(R 6 ) 2 , —N + (R 4 ) 2 R 5 , or —N + R 4 (R 6 ) 2 ;

each R 4 is, independently, —H, alkyl, or benzyl;

R 5 is a polyol; and

each R 6 is, independently, an alkanol.

3 . The pharmaceutical composition of claim 2 , wherein M is a covalent bond, —(CH 2 ) n —, 1,3-phenylene, 1,4-phenylene, —C(O)O—, —C(O)NR 1 , —C(O)—, —O—, —NR 1 —, —CH 2 NR 1 —, or —CH 2 O—; and W is an aminoalkylpolyol or a dialkanolamine.

4 . The pharmaceutical composition of claim 1 , wherein the polymer is a polymer with monomer units represented by Structural Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

M is a 1,3-phenylene, 1,4-phenylene, —C(O)O—, —C(O)NR 1 , —C(O)—, —O—, —NR 1 —, —CH 2 NR 1 — or —CH 2 O—;

Q is a covalent bond or an inert linking group;

R 1 is —H, an aliphatic group or a substituted aliphatic group;

R 2 is —H or a C1-C6 alkyl group;

W is —NR 4 R 5 , —N(R 6 ) 2 , —N + (R 4 ) 2 R 5 , or —N + R 4 (R 6 ) 2 ;

each R 4 is, independently, —H, alkyl, or benzyl;

R 5 is a polyol; and

each R 6 is, independently, an alkanol.

5 . The pharmaceutical composition of claim 3 wherein Q is a C1 to C30 alkylene group.

6 . The pharmaceutical composition of claim 5 wherein Q is a C1 to C15 alkylene group.

7 . The pharmaceutical composition of claim 6 wherein W is diethanolammoniumdiol or an ammoniumalkyldiol.

8 . The pharmaceutical composition of claim 5 wherein W is an aminoalkyl-1,2-diol.

9 . The pharmaceutical composition of claim 8 wherein W is aminopropane-1,2-diol.

10 . The pharmaceutical composition of claim 5 wherein W is diethanolamine.

11 . The pharmaceutical composition of claim 4 wherein W is diethanolamine and Q is a C1 to C4 alkylene group.

12 . (canceled)

13 . The pharmaceutical composition of claim 1 , wherein the polymer is a polymer with monomer units represented by Structural Formula (II):

or a pharmaceutically acceptable salt thereof;

wherein:

Q is a covalent bond or an inert linking group;

W is —NR 4 R 5 , —N(R 6 ) 2 , —N + (R 4 ) 2 R 5 , or —N + R 4 (R 6 ) 2 ;

each R 4 is, independently, —H, alkyl, or benzyl;

R 5 is a polyol; and

each R 6 is, independently, an alkanol.

14 - 24 . (canceled)

25 . The method of claim 39 , wherein the polymer is a polymer with monomer units represented by Structural Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

M is 1,3-phenylene, 1,4-phenylene, —C(O)O—, —C(O)NR 1 , —C(O)—, —O—, —NR 1 —, —CH 2 NR 1 - or —CH 2 O—;

Q is a covalent bond or an inert linking group;

R 1 is —H, an aliphatic group or a substituted aliphatic group;

R 2 is —H or a C1-C6 alkyl group; and

W is —NR 4 R 5 , —N(R 6 ) 2 , —N + (R 4 ) 2 R 5 , or —N + R 4 (R 6 ) 2 ;

R 4 is, independently, —H, alkyl, or benzyl;

R 5 is a polyol; and

R 6 is, independently, an alkanol.

26 . The method of claim 25 , wherein the subject is obese.

27 . The method of claim 25 , wherein the subject is being treated for Type II (non-insulin-dependent) diabetes mellitus.

28 . The method of claim 25 , wherein the subject is being treated for one or more of the following conditions, selected from:

steatorrhea, impaired glucose tolerance, hypertension, coronary thrombosis, stroke, lipid syndromes, hyperglycemia, hypertriglyceridemia, hyperlipidemia, sleep apnea, hiatal hernia, reflux esophagisitis, osteoarthritis, gout, cancers associated with weight gain, gallstones, kidney stones, pulmonary hypertension, infertility, cardiovascular disease;

or wherein the subject is being treated to reduce platelet adhesiveness, to lower weight loss after pregnancy, lower lipid levels, lower uric acid levels, or lower oxalate levels.

29 - 31 . (canceled)

32 . The method of claim 40 , wherein

W is an aminoalkylpolyol or a dialkanolamine.

33 - 37 . (canceled)

38 . The pharmaceutical composition of claim 1 , wherein the polymer is a polymer with monomer units represented by Structural Formula (III):

39 . A method for removing fat from the gastrointestinal tract of a subject in need of such treatment, said method comprising the step of administering to the subject an effective amount of a polymer with one or more side chains comprising an aminoalkylpolyol, an ammoniumalkylpolyol, a dialkanolamine, a dialkanolammonium, or a pharmaceutically acceptable salt thereof, provided that the polymer is not:

a poly(N,N-diallyl-N,N-di(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof;

a poly(N,N-diallyl-N-alkyl-N-(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof; or

a poly(N,N-di(2,3-dihydroxypropyl)allylamine) or a pharmaceutically acceptable salt thereof.

40 . A method of treating a subject afflicted with a condition selected from the group consisting of Type II diabetes mellitus, impaired glucose tolerance, hypertension, coronary thrombosis, stroke, lipid syndromes, hyperglycemia, hypertriglyceridemia, hyperlipidemia, sleep apnea, hiatal hernia, reflux esophagisitis, osteoarthritis, gout, cancers associated with weight gain, gallstones, kidney stones, pulmonary hypertension, infertility and cardiovascular disease, said method comprising the step of administering to the subject an effective amount of a polymer with one or more side chains comprising an aminoalkylpolyol, an ammoniumalkylpolyol, a dialkanolamine, a dialkanolammonium, or a pharmaceutically acceptable salt thereof, provided that the polymer is not:

a poly(N,N-diallyl-N,N-di(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof;

a poly(N,N-diallyl-N-alkyl-N-(2,3-dihydroxylpropyl)amine) or a pharmaceutically acceptable salt thereof; or

a poly(N,N-di(2,3-dihydroxypropyl)allylamine) or a pharmaceutically acceptable salt thereof.